Lantern Pharma is trading at $2.10, down 10.26%, with no confirmed catalyst for the August 24 decline. - Weakness extended after the August 21, 2026 close at $2.34; no new company-specific announcement or clearly identified catalyst explains it. - Investors may still weigh the August 14 second-quarter report: $7.1 million net loss and approximately $7.4 million in cash and marketable securities; cause unconfirmed. - Broader indexes are mixed, not sharply lower; sentiment alone does not explain the decline. Confidence is low pending a filing or announcement.